Jan-Inge Henter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2695901/publications.pdf

Version: 2024-02-01

142 papers	19,959 citations	36691 53 h-index	14779 131 g-index
145 all docs	145 docs citations	145 times ranked	18104 citing authors

#	Article	IF	Citations
1	Response to mitogenâ€activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. British Journal of Haematology, 2022, 196, 248-254.	1.2	9
2	Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Critical Care Medicine, 2022, 50, 860-872.	0.4	29
3	Seasonality of birth month in patients diagnosed with Langerhans cell histiocytosis (LCH). Pediatric Research, 2022, , .	1.1	0
4	Simple Evaluation of Clinical Situation and Subtypes of Pediatric Hemophagocytic Lymphohistiocytosis by Cytokine Patterns. Frontiers in Immunology, 2022, 13, 850443.	2.2	3
5	Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. British Journal of Haematology, 2022, , .	1.2	7
6	Patients with both Langerhans cell histiocytosis and Crohnâ€™s disease highlight a common role of interleukinâ€23. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 1315-1321.	0.7	8
7	Severe congenital neutropeniaâ€associated JAGN1 mutations unleash a calpainâ€dependent cell death programme in myeloid cells. British Journal of Haematology, 2021, 192, 200-211.	1.2	7
8	Is neutralization of IFNâ€Î³ sufficient to control inflammation in HLH?. Pediatric Blood and Cancer, 2021, 68, e28886.	0.8	7
9	Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndromeâ€“Hemophagocytic Lymphohistiocytosis. Journal of Rheumatology, 2021, 48, 1596-1602.	1.0	26
10	Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome. Molecular Medicine, 2021, 27, 48.	1.9	7
11	High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	52
12	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Journal of Pediatrics, 2021, 237, 65-70.e3.	0.9	8
13	Major alterations in the mononuclear phagocyte landscape associated with COVID-19 severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	104
14	Clinical and laboratory signs of haemophagocytic lymphohistiocytosis associated with pandemic influenza A (H1N1) infection in patients needing extracorporeal membrane oxygenation. European Journal of Anaesthesiology, 2021, 38, 692-701.	0.7	1
15	Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2021, 69, 31.	1.0	4
16	Neutralizing Anti-IL-17A Antibody Demonstrates Preclinical Activity Enhanced by Vinblastine in Langerhans Cell Histiocytosis. Frontiers in Oncology, 2021, 11, 780191.	1.3	1
17	Dengue Infection Complicated by Hemophagocytic Lymphohistiocytosis: Experiences From 180 Patients With Severe Dengue. Clinical Infectious Diseases, 2020, 70, 2247-2255.	2.9	32
18	High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis. Cytokine, 2020, 126, 154877.	1.4	10

#	Article	IF	Citations
19	Comparison of three different ELISAs for the detection of recombinant, native and plasma IL-17A. MethodsX, 2020, 7, 100997.	0.7	0
20	Emapalumab in Primary Hemophagocytic Lymphohistiocytosis. New England Journal of Medicine, 2020, 383, 596-599.	13.9	11
21	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	13.5	1,561
22	Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study. Blood Advances, 2020, 4, 3754-3766.	2.5	34
23	Ribonucleotide reductase inhibitors suppress <scp>SAMHD</scp> 1 araâ€•<scp>CTP</scp> ase activity enhancing cytarabine efficacy. EMBO Molecular Medicine, 2020, 12, e10419.	3.3	35
24	Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity. Clinical Immunology, 2020, 215, 108418.	1.4	14
25	Expression of concern to: High systematic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Molecular Medicine, 2020, 26, 17.	1.9	0
26	Diagnostic challenges for a novel SH2D1A mutation associated with Xâ€linked lymphoproliferative disease. Pediatric Blood and Cancer, 2020, 67, e28184.	0.8	4
27	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood, 2019, 133, 2465-2477.	0.6	587
28	Haploinsufficiency of UNC13D increases the risk of lymphoma. Cancer, 2019, 125, 1848-1854.	2.0	8
29	Elevated ferritin and soluble CD25 in critically ill patients are associated with parameters of (hyper) inflammation and lymphocyte cytotoxicity. Minerva Anestesiologica, 2019, 85, 1289-1298.	0.6	13
30	Etoposide Therapy of Cytokine Storm Syndromes. , 2019, , 521-547.		0
31	A RAB27A 5â€² untranslated region structural variant associated with late-onset hemophagocytic lymphohistiocytosis and normal pigmentation. Journal of Allergy and Clinical Immunology, 2018, 142, 317-321.e8.	1.5	22
32	Treatment of Newly Diagnosed HLH and Refractory Disease. , 2018, , 247-263.		0
33	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer Journal, 2018, 8, 98.	2.8	28
34	Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1508-1517.	2.0	112
35	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nature Medicine, 2017, 23, 256-263.	15.2	102
36	How to Treat Involvement of the Central Nervous System in Hemophagocytic Lymphohistiocytosis?. Current Treatment Options in Neurology, 2017, 19, 3.	0.7	90

#	Article	IF	Citations
37	SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle, 2017, 16, 1029-1038.	1.3	56
38	With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. Experimental Hematology, 2017, 52, 32-39.	0.2	43
39	Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood, 2017, 130, 2728-2738.	0.6	418
40	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	0.9	50
41	Differences in Granule Morphology yet Equally Impaired Exocytosis among Cytotoxic T Cells and NK Cells from Chediakâ€“Higashi Syndrome Patients. Frontiers in Immunology, 2017, 8, 426.	2.2	26
42	Clinical presentation of hemophagocytic lymphohistiocytosis in adults is less typical than in children. Clinics, 2016, 71, 205-209.	0.6	23
43	Successful Hematopoietic Stem Cell Transplantation in a Patient with LPS-Responsive Beige-Like Anchor (LRBA) Gene Mutation. Journal of Clinical Immunology, 2016, 36, 480-489.	2.0	30
44	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 3281-3290.	0.6	83
45	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	0.6	1,040
46	Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis. Blood, 2016, 128, 1302-1305.	0.6	11
47	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	2.9	427
48	Children with cancer share their views: tell the truth but leave room for hope. Acta Paediatrica, International Journal of Paediatrics, 2016, 105, 1094-1099.	0.7	51
49	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	1.8	57
50	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.5	338
51	Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD. Gut, 2016, 65, 1632-1641.	6.1	87
52	Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis. Genome Medicine, 2015, 7, 130.	3.6	37
53	Spectrum of Atypical Clinical Presentations in Patients with Biallelic PRF1 Missense Mutations. Pediatric Blood and Cancer, 2015, 62, 2094-2100.	0.8	38
54	Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-Î³ receptor deficiency. Journal of Allergy and Clinical Immunology, 2015, 135, 1638-1641.e5.	1.5	69

#	Article	IF	Citations
55	Cancer risk in relatives of patients with a primary disorder of lymphocyte cytotoxicity: a retrospective cohort study. Lancet Haematology,the, 2015, 2, e536-e542.	2.2	32
56	Incidence and clinical presentation of primary hemophagocytic lymphohistiocytosis in Sweden. Pediatric Blood and Cancer, 2015, 62, 346-352.	0.8	63
57	Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica, 2015, 100, 997-1004.	1.7	135
58	High Systemic Levels of the Cytokine-Inducing HMGB1 Isoform Secreted in Severe Macrophage Activation Syndrome. Molecular Medicine, 2014, 20, 538-547.	1.9	45
59	An N-Terminal Missense Mutation in STX11 Causative of FHL4 Abrogates Syntaxin-11 Binding to Munc18-2. Frontiers in Immunology, 2014, 4, 515.	2.2	20
60	Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity. Experimental Cell Research, 2014, 325, 10-17.	1.2	38
61	Combined newborn screening for familial hemophagocytic lymphohistiocytosis and severe T- and B-cell immunodeficiencies. Journal of Allergy and Clinical Immunology, 2014, 134, 226-228.e7.	1.5	20
62	Detection of IL-17A-producing peripheral blood monocytes in Langerhans cell histiocytosis patients. Clinical Immunology, 2014, 153, 112-122.	1.4	24
63	Polyclonal T-Cells Express CD1a in Langerhans Cell Histiocytosis (LCH) Lesions. PLoS ONE, 2014, 9, e109586.	1.1	6
64	Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production. Blood, 2013, 121, 1345-1356.	0.6	122
65	Novel deep intronic and missense <scp>UNC</scp>13<scp>D</scp> mutations in familial haemophagocytic lymphohistiocytosis type 3. British Journal of Haematology, 2013, 162, 415-418.	1.2	39
66	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood, 2013, 121, 5006-5014.	0.6	343
67	Development of classical Hodgkin's lymphoma in an adult with biallelic STXBP2 mutations. Haematologica, 2013, 98, 760-764.	1.7	35
68	Treatment of Familial Hemophagocytic Lymphohistiocytosis with Third-Party Mesenchymal Stromal Cells. Stem Cells and Development, 2012, 21, 3147-3151.	1.1	19
69	Langerhans cell histiocytosis in children born 1982â€“2005 after in vitro fertilization. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 1151-1155.	0.7	15
70	A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood, 2012, 119, 2754-2763.	0.6	263
71	Risk factors for early death in children with haemophagocytic lymphohistiocytosis. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 313-318.	0.7	69
72	The need for worldwide policy and action plans for rare diseases. Acta Paediatrica, International Journal of Paediatrics, 2012, 101, 805-807.	0.7	69

#	Article	IF	Citations
73	Killer cell immunoglobulinâ€like receptor gene polymorphisms predispose susceptibility to Epsteinâ€Barr virus associated hemophagocytic lymphohistiocytosis in Chinese children. Microbiology and Immunology, 2012, 56, 378-384.	0.7	9
74	Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood, 2011, 118, 4577-4584.	0.6	493
75	Genotype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. Journal of Medical Genetics, 2011, 48, 343-352.	1.5	76
76	Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood, 2011, 118, 5783-5793.	0.6	115
77	Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: A population based study. Pediatric Blood and Cancer, 2011, 56, 250-257.	0.8	58
78	Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood, 2010, 116, 2635-2643.	0.6	108
79	Central Nervous System Disease in Langerhans Cell Histiocytosis. Journal of Pediatrics, 2010, 156, 873-881.e1.	0.9	193
80	Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2010, 54, 408-415.	0.8	58
81	Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatric Blood and Cancer, 2010, 54, 563-572.	0.8	82
82	Cytotoxic therapy for severe swine flu A/H1N1. Lancet, The, 2010, 376, 2116.	6.3	37
83	Treatment of the Xâ€linked lymphoproliferative, Griscelli and ChÃ©diakâ€“Higashi syndromes by HLH directed therapy. Pediatric Blood and Cancer, 2009, 52, 268-272.	0.8	33
84	Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2009, 53, 1264-1270.	0.8	22
85	Reply to: "Interleukin-17A is not expressed by CD207+ cells in Langerhans cell histiocytosis lesions". Nature Medicine, 2009, 15, 484-485.	15.2	6
86	Different NK cellâ€“activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood, 2009, 114, 4117-4127.	0.6	90
87	Sequence analysis of the SRGN, AP3B1, ARF6, and SH2D1A genes in familial hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2008, 50, 1067-1069.	0.8	4
88	Pronounced hyperferritinemia: Expanding the field of hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2008, 50, 1127-1129.	0.8	11
89	Incidence of Langerhans cell histiocytosis in children: A populationâ€based study. Pediatric Blood and Cancer, 2008, 51, 76-81.	0.8	179
90	Neuropsychological sequelae in patients with neurodegenerative Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2008, 51, 669-674.	0.8	16

#	Article	IF	Citations
91	Langerhans cell histiocytosis reveals a new IL-17Aâ€“dependent pathway of dendritic cell fusion. Nature Medicine, 2008, 14, 81-87.	15.2	180
92	Frequency and spectrum of central nervous system involvement in 193 children with haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2008, 140, 327-335.	1.2	217
93	Characterization of PRF1, STX11 and UNC13D genotypeâ€phenotype correlations in familial hemophagocytic lymphohistiocytosis. British Journal of Haematology, 2008, 143, 75-83.	1.2	78
94	Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood, 2007, 109, 5157-5159.	0.6	61
95	Defective cytotoxic lymphocyte degranulation in syntaxin-11â€“deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood, 2007, 110, 1906-1915.	0.6	272
96	VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochemical and Biophysical Research Communications, 2007, 363, 989-993.	1.0	59
97	Pulmonary function testing and pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2007, 49, 323-328.	0.8	10
98	HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood and Cancer, 2007, 48, 124-131.	0.8	4,018
99	Severe bacteriaâ€associated hemophagocytic lymphohistiocytosis in an extremely premature infant. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1703-1706.	0.7	14
100	Cytotoxic therapy for severe avian influenza A (H5N1) infection. Lancet, The, 2006, 367, 870-873.	6.3	85
101	Elevated Serum Levels of the Decoy Receptor Osteoprotegerin in Children with Langerhans Cell Histiocytosis. Pediatric Research, 2006, 59, 281-286.	1.1	12
102	Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2005, 129, 622-630.	1.2	206
103	Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. British Journal of Haematology, 2005, 129, 658-666.	1.2	33
104	Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Human Molecular Genetics, 2005, 14, 827-834.	1.4	502
105	Long-term follow-up of Langerhans cell histiocytosis: 39 yearsâ€™ experience at a single centre. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1073-1084.	0.7	43
106	Longâ€term followâ€up of Langerhans cell histiocytosis: 39 yearsâ€™ experience at a single centre. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1073-1084.	0.7	43
107	Identification of a MEF Gene Mutation in a Familial Hemophagocytic Lymphohistiocytosis Patient That Decreases MEF Transcriptional Activity.. Blood, 2005, 106, 3013-3013.	0.6	0
108	Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Annals of Neurology, 2004, 56, 564-567.	2.8	145

#	Article	IF	Citations
109	Tumor Necrosis Factor, Interleukin 11, and Leukemia Inhibitory Factor Produced by Langerhans Cells in Langerhans Cell Histiocytosis. Journal of Pediatric Hematology/Oncology, 2004, 26, 706-711.	0.3	29
110	Langerhans-cell histiocytosis: neoplasia or unbridled inflammation?. Trends in Immunology, 2003, 24, 409-410.	2.9	32
111	Clinical and Genetic Studies of Familial Hemophagocytic Lymphohistiocytosis in Oman: Need for Early Treatment. Pediatric Hematology and Oncology, 2003, 20, 603-609.	0.3	13
112	Immunogenetic Heterogeneity in Single-System and Multisystem Langerhans Cell Histiocytosis. Pediatric Research, 2003, 54, 30-36.	1.1	22
113	Clinical and Genetic Studies of Familial Hemophagocytic Lymphohistiocytosis in Oman: Need for Early Treatment. Pediatric Hematology and Oncology, 2003, 20, 603-609.	0.3	1
114	Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood, 2002, 100, 2367-2373.	0.6	737
115	Brain 18-FDG PET scan in central nervous system langerhans cell histiocytosis. Journal of Pediatrics, 2002, 141, 435-440.	0.9	36
116	Biology and treatment of familial hemophagocytic lymphohistiocytosis: Importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Medical and Pediatric Oncology, 2002, 38, 305-309.	1.0	72
117	Spectrum of Perforin Gene Mutations in Familial Hemophagocytic Lymphohistiocytosis. American Journal of Human Genetics, 2001, 68, 590-597.	2.6	246
118	Familial Hemophagocytic Lymphohistiocytosis: Too Little Cell Death Can Seriously Damage Your Health. Leukemia and Lymphoma, 2001, 42, 13-20.	0.6	28
119	Pulmonary abnormalities at long-term follow-up of patients with Langerhans cell histiocytosis. Medical and Pediatric Oncology, 2001, 36, 459-468.	1.0	50
120	Successful Treatment of Langerhans'-Cell Histiocytosis with Etanercept. New England Journal of Medicine, 2001, 345, 1577-1578.	13.9	78
121	Detection of Langerhans cell histiocytosis lesions with somatostatin analogue scintigraphy?a preliminary report. Medical and Pediatric Oncology, 2000, 35, 462-467.	1.0	15
122	Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients. British Journal of Haematology, 1999, 106, 406-415.	1.2	44
123	Successful extracorporeal membrane oxygenation in four children with malignant disease and severePneumocystis carinii pneumonia. , 1999, 32, 25-31.		27
124	Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis. Science, 1999, 286, 1957-1959.	6.0	1,074
125	Persistent B19 parvovirus infection in pediatric malignancies. , 1998, 31, 66-72.		39
126	FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS. Hematology/Oncology Clinics of North America, 1998, 12, 417-433.	0.9	241

#	Article	IF	Citations
127	INFECTION- AND MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC SYNDROMES. Hematology/Oncology Clinics of North America, 1998, 12, 435-444.	0.9	376
128	Persistent B19 parvovirus infection in pediatric malignancies. Medical and Pediatric Oncology, 1998, 31, 66-72.	1.0	2
129	Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. Journal of Pediatrics, 1997, 130, 358-365.	0.9	189
130	HLH-94: A treatment protocol for hemophagocytic lymphohistiocytosis. , 1997, 28, 342-347.		417
131	Contemporary classification of histiocytic disorders. , 1997, 29, 157-166.		740
132	HLHâ€94: A treatment protocol for hemophagocytic lymphohistiocytosis. Medical and Pediatric Oncology, 1997, 28, 342-347.	1.0	24
133	Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. , 1996, 27, 21-25.		43
134	Elevated circulating levels of interleukin-1 receptor antagonist but not IL-1 agonists in hemophagocytic lymphohistiocytosis. , 1996, 27, 21.		1
135	HAEMOPHAGOCYTICLYMPHOHISTIOCYTOSIS: AN INHERITED PRIMARY FORM AND A REACTIVE SECONDARY FORM. British Journal of Haematology, 1995, 91, 774-775.	1.2	9
136	Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 369-372.	0.7	123
137	Lipoprotein alterations in children with bacterial meningitis. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 694-698.	0.7	9
138	Kalaâ€azar in a oneâ€yearâ€old Swedish child. Diagnostic difficulties because of active hemophagocytosis. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 794-796.	0.7	31
139	Incidence in Sweden and Clinical Features of Familial Hemophagocytic Lymphohistiocytosis. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 428-435.	0.7	362
140	Familial Hemophagocytic Lymphohistiocytosis: Clinical Review Based on the Findings in Seven Children. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 269-277.	0.7	55
141	SUCCESSFUL INDUCTION WITH CHEMOTHERAPY INCLUDING TENIPOSIDE IN FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS. Lancet, The, 1986, 328, 1402.	6.3	42
142	Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions. Frontiers in Pediatrics, 0, 10, .	0.9	2